Avacta moves on to next phase of trial
THE YORKSHIRE-BASED Avacta Group aims to save lives by developing ground-breaking and affordable cancer treatments.
Avacta Group has announced that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the next dose cohort following a positive review of the safety data from the initial cohort.
The statement said: “Avacta’s Safety Data Monitoring Committee (SDMC) has completed its review of the safety data from the first cohort dosed with AVA6000 at 80mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 120mg/m2.
“AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION platform to improve its safety and therapeutic index. Anthracyclines such as doxorubicin, a generic chemotherapy with a market size that is expected to grow to $1.38bn by 2024, are widely used as part of standard of care in several tumour types, but their use is limited by cumulative toxicity.”
Dr Alastair Smith, chief executive officer of Avacta Group, commented: “We are delighted with the SDMC’s recommendation to move on to the next dose of AVA6000 in our dose escalation study following its positive review of the safety data from patients in the first cohort.
“We are very excited by the potential of AVA6000, and the pre|CISION platform more broadly, to deliver ground-breaking and affordable cancer treatments that have the potential to significantly improve patients’ lives.”